Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

NCT06105021 is registered in ClinicalTrials.gov with Affini-T Therapeutics, Inc. as lead sponsor.

NCT NCT06105021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06105021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
Lead sponsor
Affini-T Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 6, 2024
Completion date
December 31, 2029
Enrollment
100 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, kras g12v, non-small cell lung cancer, pancreatic ductal adenocarcinoma, solid tumor